News

Friday, 20 April 2012 - 11:43

 

The TAC National Council has resolved to seek admission in a legal dispute between the brand name drug company Aventis Pharma and the generic company Cipla, over a claim of patent infringement on a drug that treats cancer called Docetaxel. SECTION27 will act as attorneys for TAC. This briefing note sets out the background to the legal dispute and explains why TAC is arguing that the Supreme Court of Appeal must consider the right of access to health care services when it judges this dispute.

 

...

Read more
Friday, 13 April 2012 - 15:16

Please join us for an evening filled with fabulous fun to raise funds for the Treatment Action Campaign  the World's most effective Aids group.

Your R100 cover charge will go straight to the TAC and includes a show by the amazing Odidiva, a raffle ticket and a live auction. See attached for more info.

Please pass this on to anyone who you think may be...

Read more
Thursday, 5 April 2012 - 12:25

On Friday 16 March 2012 health workers, counselling organisations, activists and the National Department of Health met in Hillbrow to discuss how to improve HIV testing and counselling. The meeting was hosted by the Southern African HIV Clinicians Society, the Treatment Action Campaign and SECTION27.

Joint Statement by the Southern African HIV Clinicians Society, Treatment Action Campaign, SECTION27, WITS Reproductive Health & HIV Institute, iTEACH, Marlise Richter, Children’s Rights Centre, the Yezingane Network, Society for Family Health, MSF (Doctors Without Borders)...

Read more
Friday, 30 March 2012 - 10:38

The Treatment Action Campaign (TAC) is deeply concerned about reports of stock shortages of the essential antiretroviral medicine, tenofovir, in the public health system. Tenofovir is part of the standard regimen prescribed to people with HIV initiating antiretroviral treatment. It is a potent suppressor of HIV with an excellent side effect profile. It is a life-saving drug and one of the most important in the public health system.

FOR WIDEST DISTRIBUTION

29 March 2012
 
The Treatment Action Campaign (TAC) is deeply concerned about...
Read more
Tuesday, 27 March 2012 - 10:01

A Treatment Action Campaign briefing document

Background
 
The Agreement on Trade Related Aspects of Intellectual Property (“the TRIPS agreement”), effective from 1 January 1995, set standards of intellectual property protection that member states of the World Trade Organisation (WTO) are required to uphold in their own national laws.[1]
 
The TRIPS agreement requires WTO member countries to provide 20 years of patent protection on pharmaceuticals and all other products that meet patentability criteria (previously South Africa...
Read more

Pages